Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible therapeutic vaccine platforms. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Investment Perspective

Scancell’s outlook has been transformed by the recent investment by Redmile of a further £12.1m in equity and £17.9m in Convertible Loan Notes (CLN). These funds, together with an over-subscribed £3m Open Offer, boost Scancell’s cash to c £48m. After a sustained period of being under-resourced, attention now turns to execution and delivery. The additional funds will be used to progress and broaden the ImmunoBody and Moditope portfolios and further develop the Avidimab platform. The onus will inevitably shift to timely progress across a broader front, including clinical data for SCIB1, Modi-1, and COVIDITY and, in time, material commercial partnerships for Avidimab. We update our valuation to £144m (17.7p per share).

Market information

SymbolPrimary exchanges


H121 results highlight shift to delivery and execution
Lighthouse | 29 Jan 2021
Redmile funding releases the brakes
Update | 17 Nov 2020
Redmile endorses technologies with a further £30m
Lighthouse | 12 Oct 2020

Recent News

Update on SCIB2 clinical development partnership
03 Feb 2021
Interim results for six months ended 31 October 2020
29 Jan 2021
COVID-19 vaccine candidate selected
18 Dec 2020
Appointment of CMO and Medical Director
17 Nov 2020